Syntimmune
Boston
About Syntimmune
Syntimmune is a clinical-stage biotechnology company developing differentiated drug candidates in a wide range of autoimmune diseases. It is seeking advancing novel therapies based on its expertise in the biology of the neonatal Fc receptor (FcRn) and its role in the pathogenesis of IgG-mediated autoimmune diseases. Laurence and Richard Blumberg founded Syntimmune in 2013. Its headquarters is in Boston in Massachusetts.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $10K – $50K
- Total funding: $76.0M
- Funding stage: M&A
- Last round: Series B (Jun 2017)
- Website: syntimmune.com
- Phone: 617-206-4220
Industries & Categories
Biotechnology, Emergency Medicine, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/syntimmune-110190 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.